SAFETY, EFFICACY AND RISK OF COMPLICATIONS FOR CIRRHOTIC HCV PATIENTS WITH THROMBOCYTOPENIA AND HYPOALBUMINEMIA TREATED WITH OMBITASVIR/PARITAPREVIR/R+DASABUVIR+RIBAVIRIN  – A REAL LIFE COHORT

(1) Fundeni Clinical Institute,Bucharest,Romania

(2) Fundeni Clinical Institute,Bucuresti,Romania

(3) UMF Iasi,Iasi,Romania

(4) "Grigore T. Popa" University of Medicine and Pharmacy Iasi,Gastroenterology,Iasi,Romania

(5) Institute of Gastroenterology and Hepatology,Iasi,Romania

(6) University of Medicine and Pharmacy Victor Babes Timisoara,Department of Gastroenterology and Hepatology,Timisoara,Romania

(7) Oradea Regional Hospital,Oradea,Romania

(8) County Hospital Timisoara Gastroenterology,Dept. of Gastroenterology,Timisoara,Romania

(9) Matei Bals Clinical Institute,Bucharest,Romania

(10) UMF Craiova,Craiova,Romania

(11) Fabrio Turism,Third Medical Clinic,Cluj Napoca,Romania

(12) FUNDENI CLINICAL INSTITUTE,Gastroenterology and Hepatology,Bucharest,Romania

(13) Fundeni Clinical Institute Dept. of Gastroenterology,Gastroenterology,Bucharest,Romania

(14) Carol Davila University of Medicine and Pharmacy,Gastroenterology And Hepatology,Bucharest,Romania

(15) Fundeni Clinical Institute,Department of Gastroenterology,Bucharest,Romania



This item was part of UEG Week 2017

This item can be cited as: United European Gastroenterology Journal 2017; 5 (Supplement 1)